+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
U.S. Biologics Contract Development Market Forecast to 2033- Product Image
U.S. Biologics Contract Development Market Forecast to 2033- Product Image
New

U.S. Biologics Contract Development Market Forecast to 2033

  • PDF Icon

    Report

  • 100 Pages
  • October 2025
  • Region: United States
  • Grand View Research
  • ID: 6189364
REQUEST CUSTOMIZATION
Description Jump to:
The U.S. biologics contract development market size was estimated at USD 2.82 billion in 2024 and is projected to reach USD 4.48 billion by 2033, growing at a CAGR of 5.3% from 2025 to 2033. Factors such as growing M&A activities; increasing adoption of advanced technologies for biological production; investment, a favorable regulatory environment for clinical trials in developing countries, and a rise in outsourcing of R&D activities by pharma and biopharma companies are driving the market.

High upfront costs, regulatory burdens, and the need for speed-to-market have led many pharmaceutical and biotech firms to outsource development and manufacturing to Contract Development and Manufacturing Organization (CDMOs). Small and mid-sized biotech companies in the U.S. biologics contract development industry, in particular, rely mostly on CDMOs due to limited in-house capabilities.

Furthermore, the rising prevalence of chronic diseases, such as cardiovascular disorders, neurological disorders, and cancer, fuels the demand for novel biologic therapies. According to a report published by the CDC in February 2024, chronic diseases such as heart disease, diabetes, and obesity are a major health challenge in the U.S., affecting about 129 million people. Many Americans live with more than one chronic condition, which is putting heavy pressure on the healthcare system, as about 90% of the country’s USD 4.1 trillion annual healthcare spending goes toward managing these illnesses.

U.S. Biologics Contract Development Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. biologics contract development market report based on source, product service, and indication:

Source Outlook (Revenue, USD Million, 2021-2033)

  • Mammalian
  • Microbial
  • Others

Product Service Outlook (Revenue, USD Million, 2021-2033)

  • Cell Line Development
  • Process Development

Indication Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Source
1.2.2. Product Service
1.2.3. Indication
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Source Outlook
2.2.2. Product Service Outlook
2.2.3. Indication Outlook
2.3. Competitive Insights
Chapter 3. U.S. Biologics Contract Development Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Biologics Contract Development Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. U.S. Biologics Contract Development Market: Source Estimates & Trend Analysis
4.1. Source Segment Dashboard
4.2. U.S. Biologics Contract Development Market: Source Movement Analysis
4.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Source, 2021-2033 (USD Million)
4.3.1. Microbial
4.3.1.1. Market Estimates and Forecasts 2021-2033 (USD Million)
4.3.2. Mammalian
4.3.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
4.3.3. Others
4.3.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
Chapter 5. U.S. Biologics Contract Development Market: Product Service Estimates & Trend Analysis
5.1. Product Service Segment Dashboard
5.2. U.S. Biologics Contract Development Market: Product Service Movement Analysis
5.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Product Service, 2021-2033 (USD Million)
5.3.1. Cell Line Development
5.3.1.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.1.2. Microbial
5.3.1.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.1.3. Mammalian
5.3.1.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.1.4. Others
5.3.1.4.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2. Process Development
5.3.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.2. Upstream
5.3.2.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.2.2. Microbial
5.3.2.2.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.2.3. Mammalian
5.3.2.2.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.2.4. Others
5.3.2.2.4.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3. Downstream
5.3.2.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.2. Bioanalytical Methods
5.3.2.3.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.2.2. Impurity, isolation, & identification
5.3.2.3.2.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.2.3. Physicochemical characterization
5.3.2.3.2.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.2.4. Pharmaceutical analysis
5.3.2.3.2.4.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.2.5. Others
5.3.2.3.2.5.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.3. Product
5.3.2.3.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.3.2. MABs
5.3.2.3.3.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.3.3. Recombinant proteins
5.3.2.3.3.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
5.3.2.3.3.4. Others
5.3.2.3.3.4.1. Market Estimates and Forecasts 2021-2033 (USD Million)
Chapter 6. U.S. Biologics Contract Development Market: Indication Estimates & Trend Analysis
6.1. Indication Segment Dashboard
6.2. U.S. Biologics Contract Development Market: Indication Movement Analysis
6.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Indication, 2021-2033 (USD Million)
6.3.1. Oncology
6.3.1.1. Market Estimates and Forecasts 2021-2033 (USD million)
6.3.2. Immunological Disorders
6.3.2.1. Market Estimates and Forecasts 2021-2033 (USD Million)
6.3.3. Cardiovascular Disorders
6.3.3.1. Market Estimates and Forecasts 2021-2033 (USD Million)
6.3.4. Hematological Disorders
6.3.4.1. Market Estimates and Forecasts 2021-2033 (USD Million)
6.3.5. Others
6.3.5.1. Market Estimates and Forecasts 2021-2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, by Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. WuXi Biologics.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Abzena
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. FUJIFILM Diosynth Biotechnologies.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. KBI Biopharma
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. AGC Biologics.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Thermo Fisher Scientific Inc.
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Curia Global, Inc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. GenScript
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Bionova Scientific LLC
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Boehringer Ingelheim International
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. STC Biologics
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. biologics contract development market, by source, 2021-2033 (USD Million)
Table 3 U.S. biologics contract development market, by product service, 2021-2033 (USD Million)
Table 4 U.S. biologics contract development market, by indication, 2021-2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 U.S. biologics contract development market: market outlook
Figure 10 U.S. biological contract development competitive insights
Figure 11 Parent market outlook
Figure 12 Related/ancillary market outlook
Figure 13 Penetration and growth prospect mapping
Figure 14 Industry value chain analysis
Figure 15 U.S. biologics contract development market driver impact
Figure 16 U.S. biologics contract development market restraint impact
Figure 17 U.S. biologics contract development market strategic initiatives analysis
Figure 18 U.S. biologics contract development market: source movement analysis
Figure 19 U.S. biologics contract development market: source outlook and key takeaways
Figure 20 Microbial market estimates and forecast, 2021-2033 (USD Million)
Figure 21 Mammalian market estimates and forecast, 2021-2033 (USD Million)
Figure 22 Others estimates and forecast, 2021-2033 (USD Million)
Figure 23 U.S. biologics contract development market: product service movement analysis
Figure 24 U.S. biologics contract development market: product service outlook and key takeaways
Figure 25 Cell line development (2-17 years) market estimates and forecast, 2021-2033 (USD Million)
Figure 26 Microbial market estimates and forecast, 2021-2033 (USD Million)
Figure 27 Mammalian market estimates and forecast, 2021-2033 (USD Million)
Figure 28 Others market estimates and forecast, 2021-2033 (USD Million)
Figure 29 Process development market estimates and forecast, 2021-2033 (USD Million)
Figure 30 Upstream market estimates and forecast, 2021-2033 (USD Million)
Figure 31 Microbial market estimates and forecast, 2021-2033 (USD Million)
Figure 32 Mammalian market estimates and forecast, 2021-2033 (USD Million)
Figure 33 Others market estimates and forecast, 2021-2033 (USD Million)
Figure 34 Downstream market estimates and forecast, 2021-2033 (USD Million)
Figure 35 Analytical methods market estimates and forecast, 2021-2033 (USD Million)
Figure 36 Impurity, isolation, & identification market estimates and forecast, 2021-2033 (USD Million)
Figure 37 Physicochemical characterization market estimates and forecast, 2021-2033 (USD Million)
Figure 38 Pharmaceutical analysis market estimates and forecast, 2021-2033 (USD Million)
Figure 39 Others market estimates and forecast, 2021-2033 (USD Million)
Figure 40 Product market estimates and forecast, 2021-2033 (USD Million)
Figure 41 MABs market estimates and forecast, 2021-2033 (USD Million)
Figure 42 Recombinant proteins market estimates and forecast, 2021-2033 (USD Million)
Figure 43 Others market estimates and forecast, 2021-2033 (USD Million)
Figure 44 U.S. biologics contract development market: indication movement analysis
Figure 45 U.S. biologics contract development market: indication outlook and key takeaways
Figure 46 Hospital pharmacy estimates and forecast, 2021-2033 (USD Million)
Figure 47 Oncology market estimates and forecast, 2021-2033 (USD Million)
Figure 48 Immunological Disorders market estimates and forecast, 2021-2033 (USD Million)
Figure 49 Cardiovascular Disorders market estimates and forecast, 2021-2033 (USD Million)
Figure 50 Hematological Disorders market estimates and forecast, 2021-2033 (USD Million)
Figure 51 Others market estimates and forecast, 2021-2033 (USD Million)

Companies Mentioned

The companies profiled in this U.S. Biologics Contract Development market report include:
  • WuXi Biologics.
  • Abzena
  • FUJIFILM Diosynth Biotechnologies.
  • KBI Biopharma
  • AGC Biologics.
  • Thermo Fisher Scientific Inc.
  • Curia Global, Inc.
  • GenScript
  • Bionova Scientific LLC
  • Boehringer Ingelheim International GmbH.
  • STC Biologics

Table Information

Report AttributeDetails
No. of Pages100
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 2.82 Billion
Forecasted Market Value ( USD ) by 2033 $ 4.48 Billion
Compound Annual Growth Rate5.3%
Regions CoveredUnited States
No. of Companies Mentioned12

Related Topics

Related Reports

Biologics Manufacturing Market Size, Share & Trends Analysis Report by Mode of Manufacturing (Contract, in-House), Modality, Disease Indication, and Region with Growth Forecasts, 2025-2033 - Product Image

Biologics Manufacturing Market Size, Share & Trends Analysis Report by Mode of Manufacturing (Contract, in-House), Modality, Disease Indication, and Region with Growth Forecasts, 2025-2033

  • Report
  • 120 Pages
  • Global
From
Biopharmaceutical Contract Development and Manufacturing Organization Market Forecast to 2033 - Product Image

Biopharmaceutical Contract Development and Manufacturing Organization Market Forecast to 2033

  • Report
  • 120 Pages
  • Global
From
Biologics Contract Development and Manufacturing Organization Market Forecast to 2033 - Product Image

Biologics Contract Development and Manufacturing Organization Market Forecast to 2033

  • Report
  • 120 Pages
  • Global
From
U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report by Indication (Infectious Diseases, Metabolic & Genetic Diseases), by Application, by End Use, and Segment Forecasts, 2025-2033 - Product Image

U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report by Indication (Infectious Diseases, Metabolic & Genetic Diseases), by Application, by End Use, and Segment Forecasts, 2025-2033

  • Report
  • 120 Pages
  • United States
From
Biopharmaceutical Contract Research Organization Market Forecast to 2033 - Product Image

Biopharmaceutical Contract Research Organization Market Forecast to 2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.